CL2021000049A1 - Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso (solicitud divisional de 2456-2018) - Google Patents
Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso (solicitud divisional de 2456-2018)Info
- Publication number
- CL2021000049A1 CL2021000049A1 CL2021000049A CL2021000049A CL2021000049A1 CL 2021000049 A1 CL2021000049 A1 CL 2021000049A1 CL 2021000049 A CL2021000049 A CL 2021000049A CL 2021000049 A CL2021000049 A CL 2021000049A CL 2021000049 A1 CL2021000049 A1 CL 2021000049A1
- Authority
- CL
- Chile
- Prior art keywords
- eribulin
- methods
- antibody
- drug
- divisional application
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 3
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 abstract 1
- 229960003649 eribulin Drugs 0.000 abstract 1
- 102000006815 folate receptor Human genes 0.000 abstract 1
- 108020005243 folate receptor Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen toxinas enlazadoras y conjugados de anticuerpo-fármaco que se unen a antígenos diana de oncología humana tal como receptor de folato alfa y/o proporcionan actividad de fármaco anti-tubulina. Las toxinas enlazadoras y conjugados de anticuerpo-fármaco comprenden un resto de fármaco de eribulina y se pueden internalizar en células que expresan el antígeno diana. La descripción además se refiere a métodos y composiciones para utilizar en el tratamiento de cáncer mediante la administración de los conjugados de anticuerpo-fármaco proporcionados en la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662302562P | 2016-03-02 | 2016-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000049A1 true CL2021000049A1 (es) | 2021-05-28 |
Family
ID=58347964
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002456A CL2018002456A1 (es) | 2016-03-02 | 2018-08-28 | Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso |
CL2021000048A CL2021000048A1 (es) | 2016-03-02 | 2021-01-07 | Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso (solicitud divisional de 2456-2018) |
CL2021000049A CL2021000049A1 (es) | 2016-03-02 | 2021-01-07 | Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso (solicitud divisional de 2456-2018) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002456A CL2018002456A1 (es) | 2016-03-02 | 2018-08-28 | Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso |
CL2021000048A CL2021000048A1 (es) | 2016-03-02 | 2021-01-07 | Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso (solicitud divisional de 2456-2018) |
Country Status (34)
Country | Link |
---|---|
US (4) | US10548986B2 (es) |
EP (2) | EP3423105B1 (es) |
JP (5) | JP6599019B2 (es) |
KR (4) | KR20220101204A (es) |
CN (4) | CN108883198B (es) |
AR (3) | AR107787A1 (es) |
AU (2) | AU2017225982B2 (es) |
BR (1) | BR112018067379A2 (es) |
CA (1) | CA3013791A1 (es) |
CL (3) | CL2018002456A1 (es) |
CO (1) | CO2018008667A2 (es) |
CY (1) | CY1124628T1 (es) |
DK (1) | DK3423105T3 (es) |
ES (1) | ES2880402T3 (es) |
HR (1) | HRP20211125T1 (es) |
HU (1) | HUE054726T2 (es) |
IL (2) | IL292946A (es) |
JO (3) | JOP20170053B1 (es) |
LT (1) | LT3423105T (es) |
MA (1) | MA45280B1 (es) |
MD (1) | MD3423105T2 (es) |
MX (4) | MX2018010562A (es) |
MY (1) | MY189113A (es) |
PE (3) | PE20181953A1 (es) |
PH (1) | PH12018501847A1 (es) |
PL (1) | PL3423105T3 (es) |
PT (1) | PT3423105T (es) |
RS (1) | RS62108B1 (es) |
RU (2) | RU2754369C2 (es) |
SG (2) | SG10202007520WA (es) |
SI (1) | SI3423105T1 (es) |
TW (2) | TWI825834B (es) |
UA (1) | UA125024C2 (es) |
WO (1) | WO2017151979A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009521206A (ja) * | 2005-04-22 | 2009-06-04 | モルフォテック、インク. | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Jcr製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
WO2016208696A1 (ja) | 2015-06-24 | 2016-12-29 | Jcrファーマ株式会社 | Bdnfを含む融合蛋白質 |
AR110586A1 (es) | 2016-12-26 | 2019-04-10 | Japan Chem Res | Anticuerpo de receptor antitransferrina humana que penetra la barrera hematoencefálica |
EP4119563A3 (en) | 2017-04-05 | 2023-04-05 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
JP7370313B2 (ja) | 2017-07-06 | 2023-10-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハリコンドリンの合成 |
US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
KR20200086312A (ko) * | 2017-11-08 | 2020-07-16 | 야페이 상하이 바이오로그 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 | 생체분자의 컨쥬게이트 및 이의 용도 |
JP7353281B2 (ja) | 2017-11-15 | 2023-09-29 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 大環状化合物およびそれらの使用 |
TW202015739A (zh) * | 2018-06-01 | 2020-05-01 | 日商衛材R&D企管股份有限公司 | 剪接調節抗體-藥物結合物及其使用方法 |
EP3801523A2 (en) | 2018-06-01 | 2021-04-14 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
JP7458981B2 (ja) | 2018-08-06 | 2024-04-01 | 第一三共株式会社 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
CN113195541A (zh) * | 2018-12-21 | 2021-07-30 | 诺华股份有限公司 | 针对pmel17的抗体及其缀合物 |
CN110568121A (zh) * | 2019-07-11 | 2019-12-13 | 山东省药学科学院 | 一种艾日布林及含艾日布林的制剂中有关物质的检测方法 |
BR112022008756A2 (pt) * | 2019-11-07 | 2022-07-26 | Eisai R&D Man Co Ltd | Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso |
JPWO2021132166A1 (es) | 2019-12-23 | 2021-07-01 | ||
US20230144203A1 (en) * | 2020-01-22 | 2023-05-11 | Shanghai Senhui Medicine Co., Ltd. | Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine |
WO2022031150A1 (ko) * | 2020-08-07 | 2022-02-10 | 주식회사 피노바이오 | 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도 |
EP4210751A1 (en) * | 2020-09-11 | 2023-07-19 | Alexion Pharmaceuticals, Inc. | Anti-ceruloplasmin antibodies and uses thereof |
CA3196055A1 (en) * | 2020-09-28 | 2022-03-31 | Navrogen, Inc. | Composition and use of alternatively formatted anti-mesothelin antibodies for the treatment of cancer |
US20240024502A1 (en) * | 2020-10-18 | 2024-01-25 | Ardeagen Corporation | Anti-msln binding agents, conjugates thereof and methods of using the same |
CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
CN117279664A (zh) * | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
CN115429893A (zh) * | 2021-06-02 | 2022-12-06 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
AU2022316425A1 (en) | 2021-07-22 | 2024-02-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Drug conjugate of eribulin derivative |
CN118043080A (zh) * | 2021-08-13 | 2024-05-14 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
CN117881431A (zh) * | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
CN115957339A (zh) * | 2021-09-16 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物及其组合物和用途 |
WO2023055376A1 (en) * | 2021-09-30 | 2023-04-06 | Virtuoso Binco, Inc. | Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof |
CN118103359A (zh) * | 2021-10-14 | 2024-05-28 | 江苏恒瑞医药股份有限公司 | 一种艾日布林衍生物的制备方法 |
CN116199740A (zh) * | 2021-12-01 | 2023-06-02 | 上海生物制品研究所有限责任公司 | 抗体药物偶联物及其用途 |
WO2023103854A1 (zh) * | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
WO2023124963A1 (zh) * | 2021-12-27 | 2023-07-06 | 昆山新蕴达生物科技有限公司 | 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用 |
WO2023143320A1 (zh) * | 2022-01-28 | 2023-08-03 | 博瑞生物医药(苏州)股份有限公司 | 用于制备抗体药物偶联物的连接子、化合物及用途 |
WO2023143319A1 (zh) * | 2022-01-28 | 2023-08-03 | 启德医药科技(苏州)有限公司 | 抗体药物偶联物、药物组合物及用途 |
WO2023155808A1 (zh) * | 2022-02-16 | 2023-08-24 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
WO2023170247A1 (en) | 2022-03-11 | 2023-09-14 | Mablink Bioscience | Antibody-drug conjugates and their uses |
WO2023200814A1 (en) | 2022-04-12 | 2023-10-19 | Eisai R & D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
WO2023198079A1 (zh) * | 2022-04-12 | 2023-10-19 | 百奥泰生物制药股份有限公司 | 治疗her2阳性实体瘤的方法 |
WO2024078612A1 (en) * | 2022-10-14 | 2024-04-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linker-payload compound, conjugates and applications thereof |
CN117917248A (zh) * | 2022-10-20 | 2024-04-23 | 英诺湖医药(杭州)有限公司 | 酶裂解连接子及包含其的配体-艾瑞布林偶联物 |
Family Cites Families (222)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE69232706T2 (de) | 1991-05-01 | 2002-11-28 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
ES2195036T3 (es) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
PT885002E (pt) | 1996-03-04 | 2011-07-14 | Massachusetts Inst Technology | Materiais e métodos para aumento da internalização celular |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
JP2002518432A (ja) | 1998-06-24 | 2002-06-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 吸入器から放出される大多孔性粒子 |
US6019963A (en) | 1998-11-20 | 2000-02-01 | D.S.C. Products, Inc. | Deodorizing composition containing tea tree and eucalyptus oils |
US7109019B2 (en) | 1999-01-06 | 2006-09-19 | The Regents Of The University Of California | Gene cluster for production of the enediyne antitumor antibiotic C-1027 |
KR20040015234A (ko) | 2001-05-02 | 2004-02-18 | 펄듀 리서치 파운데이션 | 대식세포 매개된 질환의 치료와 진단 |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
EP1531846A4 (en) | 2002-02-27 | 2006-04-19 | Us Gov Health & Human Serv | CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES |
DK1545613T3 (da) * | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
JP2004119755A (ja) | 2002-09-27 | 2004-04-15 | Alps Electric Co Ltd | 磁気検出素子及びその製造方法 |
US20040071540A1 (en) | 2002-10-15 | 2004-04-15 | Lucas Philip J. | Disposable/recyclable pallet system and method |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
RU2006112834A (ru) | 2003-09-18 | 2007-10-27 | Комбинаторкс, Инкорпорейтед (Us) | Сочетание лекарственных средств для лечения новообразований |
US6997024B2 (en) | 2003-10-01 | 2006-02-14 | Truth Hardware Corporation | Pull door lock |
US20050148535A1 (en) | 2003-10-30 | 2005-07-07 | Lacasse Eric | IAP nucleobase oligomers and oligomeric complexes and uses thereof |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
US7117807B2 (en) | 2004-02-17 | 2006-10-10 | University Of Florida Research Foundation, Inc. | Dynamically modifiable polymer coatings and devices |
WO2006073419A2 (en) | 2004-04-01 | 2006-07-13 | Gang Zheng | Lipoprotein nanoplatforms |
US20060052951A1 (en) | 2004-05-07 | 2006-03-09 | Yaffe Michael B | Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1 |
CN104876896A (zh) | 2004-06-03 | 2015-09-02 | 卫材R&D管理有限公司 | 用于制备软海绵素b的类似物的中间体 |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20060154312A1 (en) | 2004-12-09 | 2006-07-13 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using halichondrin B analogs |
US20060148014A1 (en) | 2004-12-09 | 2006-07-06 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using hemiasterlin analogs |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
GB0515025D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
CN103893778A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
US8129505B2 (en) | 2005-09-14 | 2012-03-06 | Ucb Pharma S.A. | Comb polymers |
WO2007064691A1 (en) | 2005-12-02 | 2007-06-07 | Nabil Habib Lab | Treatment of cancer and other diseases |
WO2007128884A1 (en) | 2006-05-09 | 2007-11-15 | Oy Jurilab Ltd | Novel genes and markers in type 2 diabetes and obesity |
US20140037539A1 (en) | 2012-07-27 | 2014-02-06 | Rutgers, The State University Of New Jersey | Antibody cocktails for breast cancer radioimmunotherapy |
US20150030534A1 (en) | 2013-07-26 | 2015-01-29 | Rutgers, The State University Of New Jersey | Antibody cocktails for breast cancer radioimmunotherapy |
US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
EP2139523B1 (en) | 2007-03-14 | 2014-10-22 | Endocyte, Inc. | Conjugates of folate and tubulysin for targeted drug delivery |
EP1977765A1 (en) | 2007-04-03 | 2008-10-08 | Diatos | Peptide prodrugs |
JP5735277B2 (ja) | 2007-10-03 | 2015-06-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンb類似体の合成のための中間体および方法 |
CN101884058B (zh) | 2007-10-30 | 2012-07-25 | 富士通株式会社 | 移动终端装置 |
ES2647927T3 (es) | 2008-03-18 | 2017-12-27 | Seattle Genetics, Inc. | Conjugados enlazadores del fármaco auriestatina |
EP2279267A4 (en) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
BRPI0911442A2 (pt) * | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
AR072001A1 (es) | 2008-06-03 | 2010-07-28 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
RU2011104348A (ru) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
MX2011002677A (es) | 2008-09-12 | 2011-04-12 | Santen Pharma Co Ltd | Agonista del receptor de glucocorticoide que comprende nuevos derivados de 1,2,3,-4-tetrahidroquinoxalina que contienen un grupo fenilo que tiene una estructura de ester de acido sulfonico introducida en el mismo como sustituyente. |
AU2009322236B2 (en) | 2008-12-04 | 2013-11-07 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
PE20160651A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
US20140339088A1 (en) | 2009-03-09 | 2014-11-20 | Virginia Tech Intellectual Properties, Inc. | Dielectrophoresis methods for determining a property of a plurality of cancer cells |
BRPI1012193A2 (pt) | 2009-05-01 | 2019-09-24 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
US8686520B2 (en) * | 2009-05-29 | 2014-04-01 | International Business Machines Corporation | Spin-torque magnetoresistive structures |
UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
SG178419A1 (en) * | 2009-08-15 | 2012-04-27 | Genentech Inc | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
IN2012DN02737A (es) * | 2009-09-01 | 2015-09-11 | Abbott Lab | |
GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
JP2013510166A (ja) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物、方法およびその適用 |
MX2012008510A (es) | 2010-01-26 | 2012-11-21 | Eisai R&D Man Co Ltd | Derivados de furo [3, 2-b] pirano utiles en la sintesis de analogos de halicondrina b. |
US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
CA2794266C (en) | 2010-03-24 | 2020-09-08 | Ohio University | Compositions and methods for glucose transport inhibition |
LT2571532T (lt) | 2010-05-14 | 2017-08-10 | Abbvie Inc. | Il-1 surišantys baltymai |
JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
AR082461A1 (es) | 2010-08-03 | 2012-12-12 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
US9089570B2 (en) | 2010-09-03 | 2015-07-28 | Tactical Therapeutics Inc | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate |
WO2012031609A1 (en) | 2010-09-07 | 2012-03-15 | Johannes Kepler Universität Linz | Biodegradable, water soluble and ph responsive poly(organo)phosphazenes |
WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
CN103221072A (zh) | 2010-12-02 | 2013-07-24 | 免疫医疗公司 | 用于递送治疗剂和/或诊断剂的体内无铜催化的点击化学 |
CA2821976A1 (en) | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
EP2654792A4 (en) | 2010-12-22 | 2016-05-11 | Abbvie Inc | HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF |
WO2012112696A1 (en) | 2011-02-15 | 2012-08-23 | Vaxiion Therapeutics, Inc. | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
WO2012119077A1 (en) | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
WO2012118978A1 (en) | 2011-03-03 | 2012-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating oncovirus positive cancers |
EP2966061B1 (en) | 2011-03-04 | 2017-05-03 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
EP2685988A4 (en) | 2011-03-15 | 2014-08-20 | Univ North Carolina | METHOD FOR THE TREATMENT OF BREAST CANCER WITH ANTHRACYCLIN THERAPY |
WO2012129100A1 (en) | 2011-03-18 | 2012-09-27 | Eisai R&D Management Co., Ltd. | Methods and compositions for predicting response to eribulin |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
EP2670866A4 (en) | 2011-04-05 | 2015-09-02 | Translational Genomics Res Inst | BIOMARKERS AND METHODS OF USE |
US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
MX359217B (es) | 2011-05-27 | 2018-09-19 | Ambrx Inc | Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales. |
WO2012170640A1 (en) | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
MX368966B (es) | 2011-06-10 | 2019-10-23 | Mersana Therapeutics Inc | Conjugados de proteina-polimero-farmaco. |
PT2739649T (pt) | 2011-08-05 | 2018-01-03 | Bioasis Technologies Inc | Fragmentos de p97 com atividade de transferência |
EP2785687B1 (en) | 2011-11-30 | 2019-02-20 | Sandoz AG | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
CN104024237B (zh) | 2011-12-16 | 2016-02-24 | 阿方拉研究股份有限公司 | 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体 |
CA2859755C (en) | 2011-12-23 | 2021-04-20 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
US9062020B2 (en) | 2011-12-29 | 2015-06-23 | Alphora Research Inc. | 2-((2S,3S,4R,5R)-5-((S)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
WO2013130093A1 (en) * | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
US9358235B2 (en) * | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
WO2013148337A1 (en) | 2012-03-29 | 2013-10-03 | Altor Bioscience Corporation | Methods for treating neoplasia |
IN2014MN02106A (es) | 2012-03-30 | 2015-09-11 | Alphora Res Inc | |
JP2015514113A (ja) | 2012-04-02 | 2015-05-18 | メリマック ファーマシューティカルズ インコーポレーティッド | 単一特異性および二重特異性抗igf−1rおよび抗erbb3抗体の用法および用量 |
EP2850434A4 (en) | 2012-05-15 | 2016-01-13 | Diatech Oncology Llc | TUMOR CELL INSULATION / CLEANING METHOD AND METHOD OF USE THEREOF |
CN104662000B (zh) | 2012-05-15 | 2018-08-17 | 索伦托医疗有限公司 | 药物偶联物及其偶联方法和用途 |
SG11201408153YA (en) | 2012-06-07 | 2015-01-29 | Ambrx Inc | Prostate-specific membrane antigen antibody drug conjugates |
AU2013273489B9 (en) | 2012-06-08 | 2018-08-23 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 Kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
ES2712648T3 (es) | 2012-06-19 | 2019-05-14 | Ambrx Inc | Conjugados de fármaco de anticuerpo anti-CD70 |
US9220695B2 (en) | 2012-06-29 | 2015-12-29 | The Research Foundation For The State University Of New York | Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances |
WO2014005010A2 (en) | 2012-06-29 | 2014-01-03 | Nanostring Technologies, Inc. | Methods of treating breast cancer with gemcitabine therapy |
EP3210627B1 (en) | 2012-07-12 | 2022-12-21 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
US9872919B2 (en) | 2012-09-19 | 2018-01-23 | The Research Foundation For The State University Of New York | Prodrugs for selective anticancer therapy |
SI2903616T1 (en) | 2012-10-04 | 2018-02-28 | Ab Science | The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease |
US20150275306A1 (en) | 2012-10-10 | 2015-10-01 | Stichting Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis | Methods and means for predicting resistance to anti-cancer treatment |
WO2014063443A1 (zh) | 2012-10-22 | 2014-05-01 | Zhang Yuliang | 自冷式热力做功方法 |
CN110201186A (zh) | 2012-10-23 | 2019-09-06 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
PT2917195T (pt) | 2012-11-05 | 2018-02-09 | Pfizer | Análogos de spliceostatina |
ES2701076T3 (es) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células |
WO2014089048A1 (en) | 2012-12-03 | 2014-06-12 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
WO2014096551A1 (en) | 2012-12-21 | 2014-06-26 | Glykos Finland Oy | Linker-payload molecule conjugates |
US20150182634A1 (en) | 2012-12-28 | 2015-07-02 | Cody P. Coyne | Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action |
WO2014113794A2 (en) | 2013-01-19 | 2014-07-24 | New York University | Oligooxopiperazines for p53 reactivation |
WO2014113792A1 (en) | 2013-01-19 | 2014-07-24 | New York University | Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation |
US20140220112A1 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
CN105163720B (zh) | 2013-02-01 | 2019-10-11 | 佐尼奥尼制药股份有限公司 | 远程装载略微水溶性药物至脂质体 |
US9849193B2 (en) | 2013-02-08 | 2017-12-26 | University Of Louisville Research Foundation, Inc. | Nanoparticles for drug delivery |
JP6382231B2 (ja) | 2013-02-22 | 2018-08-29 | ユニバーシティ オブ ヒューストンUniversity Of Houston | 神経保護剤としてのホスファプラチン |
WO2014160130A1 (en) | 2013-03-13 | 2014-10-02 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
WO2015073072A1 (en) | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
US20160022829A1 (en) | 2013-03-14 | 2016-01-28 | Mersana Therapeutics, Inc. | Tubulysin compounds and conjugates thereof |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
BR112015023190A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Florida | regulação de câncer com o uso de compostos e/ou dieta naturais |
SG11201507619PA (en) | 2013-03-15 | 2015-10-29 | Ct For Drug Res And Dev | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
WO2014168721A2 (en) | 2013-04-12 | 2014-10-16 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
EP2988786A4 (en) | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS AND METHODS OF USE FOR SELECTIVE DRUG DELIVERY |
GB2513405A (en) | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
DK2991683T3 (da) | 2013-05-02 | 2019-11-04 | Glykos Finland Oy | Konjugater af et glykoprotein eller en glykan med en toksisk ladning |
EP2997017B1 (en) | 2013-05-15 | 2017-08-09 | Alphora Research Inc. | 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof |
GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
WO2014197871A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
WO2014206466A1 (en) | 2013-06-26 | 2014-12-31 | Afg Technologies S.À.R.L | Screening, diagnosis, prognostication and treatment of ovarian cancer |
AU2014286880B2 (en) | 2013-07-03 | 2017-12-14 | Sandoz Ag | Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups |
WO2015017729A1 (en) | 2013-07-31 | 2015-02-05 | Virginia Tech Intellectual Properties, Inc. | Dielectrophoresis methods for determining a property of a plurality of cancer cells |
US20160166637A1 (en) | 2013-08-02 | 2016-06-16 | Virginia Tech Intellectual Properties, Inc. | Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction |
AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
JP2016538318A (ja) | 2013-08-28 | 2016-12-08 | ステムセントリックス, インコーポレイテッド | 新規sez6モジュレーターおよび使用方法 |
CN105848671B (zh) | 2013-08-28 | 2019-12-13 | 艾伯维施特姆森特克斯有限责任公司 | 位点特异性抗体缀合方法和组合物 |
US20150072021A1 (en) | 2013-09-09 | 2015-03-12 | British Columbia Cancer Agency Branch | Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy |
WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
US20150093331A1 (en) | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
US9878049B2 (en) | 2013-10-09 | 2018-01-30 | The University Of Akron | High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy |
JP6502931B2 (ja) | 2013-10-11 | 2019-04-17 | アメリカ合衆国 | Tem8抗体およびその使用 |
KR102355745B1 (ko) | 2013-10-11 | 2022-01-26 | 아사나 바이오사이언시스 엘엘씨 | 단백질-폴리머-약물 접합체 |
WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
EP3060654B1 (en) | 2013-10-21 | 2023-03-15 | Hemoshear, LLC | In vitro model for a tumor microenvironment |
US9783549B2 (en) | 2013-11-04 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
WO2015069266A1 (en) | 2013-11-07 | 2015-05-14 | Flynn Daniel L | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
DK3546461T3 (da) | 2013-11-15 | 2021-09-13 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
RU2676486C1 (ru) | 2013-12-06 | 2018-12-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способы, предназначенные для синтеза аналогов галихондрина b |
WO2015095784A1 (en) | 2013-12-19 | 2015-06-25 | Luminus Biosciences, Inc. | Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
US20160375234A1 (en) | 2014-01-10 | 2016-12-29 | Atossa Genetic Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
AU2015205755C1 (en) | 2014-01-10 | 2020-08-13 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
CN104784699B (zh) | 2014-01-20 | 2019-05-03 | 博瑞生物医药(苏州)股份有限公司 | 叶酸受体结合配体-药物偶联物 |
EP3424537B1 (en) | 2014-02-03 | 2021-01-13 | Eidgenössiche Technische Hochschule Zürich | Small molecule drug conjugates |
KR20160136279A (ko) * | 2014-02-03 | 2016-11-29 | 국립연구개발법인 고쿠리츠간켄큐센터 | 항-조직 인자 모노클로널 항체 |
EP2913064A1 (en) | 2014-02-26 | 2015-09-02 | celares GmbH | Branched drug-linker conjugates for the coupling to biological targeting molecules |
TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Alphora研發股份有限公司 | (s)-1-((2r,3r,4s,5s)-5-烯丙-3-甲氧-4-(對甲苯磺醯甲基)四氫呋喃-2-基)-3-氨基丙-2-醇之結晶衍生物 |
AU2015228860A1 (en) | 2014-03-13 | 2016-09-08 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
US9260478B2 (en) * | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
CA2979530C (en) | 2014-04-08 | 2023-10-03 | The Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
WO2015160833A1 (en) | 2014-04-14 | 2015-10-22 | Endocyte, Inc. | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
WO2015161247A1 (en) * | 2014-04-17 | 2015-10-22 | Igenica Biotherapeutics, Inc. | Humanized anti-c16orf54 antibodies and methods of use thereof |
TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
WO2015195925A1 (en) * | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
EP3069734A1 (en) * | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
CN107921144B (zh) | 2015-06-20 | 2023-11-28 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
-
2017
- 2017-03-02 SG SG10202007520WA patent/SG10202007520WA/en unknown
- 2017-03-02 KR KR1020227022691A patent/KR20220101204A/ko not_active Application Discontinuation
- 2017-03-02 PE PE2018001578A patent/PE20181953A1/es unknown
- 2017-03-02 AU AU2017225982A patent/AU2017225982B2/en active Active
- 2017-03-02 TW TW111125421A patent/TWI825834B/zh active
- 2017-03-02 KR KR1020187028407A patent/KR102445255B1/ko active IP Right Grant
- 2017-03-02 LT LTEP17711475.8T patent/LT3423105T/lt unknown
- 2017-03-02 CN CN201780022381.5A patent/CN108883198B/zh active Active
- 2017-03-02 TW TW106106901A patent/TWI772288B/zh active
- 2017-03-02 RU RU2018134331A patent/RU2754369C2/ru active
- 2017-03-02 HU HUE17711475A patent/HUE054726T2/hu unknown
- 2017-03-02 WO PCT/US2017/020529 patent/WO2017151979A1/en active Application Filing
- 2017-03-02 DK DK17711475.8T patent/DK3423105T3/da active
- 2017-03-02 ES ES17711475T patent/ES2880402T3/es active Active
- 2017-03-02 SI SI201730837T patent/SI3423105T1/sl unknown
- 2017-03-02 KR KR1020247000482A patent/KR20240007722A/ko not_active Application Discontinuation
- 2017-03-02 KR KR1020227022690A patent/KR102456433B1/ko active IP Right Grant
- 2017-03-02 UA UAA201809739A patent/UA125024C2/uk unknown
- 2017-03-02 CN CN202111360555.3A patent/CN114191428A/zh active Pending
- 2017-03-02 JO JOP/2017/0053A patent/JOP20170053B1/ar active
- 2017-03-02 PE PE2023001171A patent/PE20231049A1/es unknown
- 2017-03-02 IL IL292946A patent/IL292946A/en unknown
- 2017-03-02 AR ARP170100524A patent/AR107787A1/es unknown
- 2017-03-02 RU RU2021125492A patent/RU2021125492A/ru unknown
- 2017-03-02 SG SG11201806515RA patent/SG11201806515RA/en unknown
- 2017-03-02 PL PL17711475T patent/PL3423105T3/pl unknown
- 2017-03-02 JP JP2018545210A patent/JP6599019B2/ja active Active
- 2017-03-02 EP EP17711475.8A patent/EP3423105B1/en active Active
- 2017-03-02 PT PT177114758T patent/PT3423105T/pt unknown
- 2017-03-02 CN CN202111360563.8A patent/CN114272389B/zh active Active
- 2017-03-02 US US15/448,497 patent/US10548986B2/en active Active
- 2017-03-02 EP EP20204172.9A patent/EP3824909A1/en active Pending
- 2017-03-02 MX MX2018010562A patent/MX2018010562A/es unknown
- 2017-03-02 CA CA3013791A patent/CA3013791A1/en active Pending
- 2017-03-02 MY MYPI2018001424A patent/MY189113A/en unknown
- 2017-03-02 PE PE2023001172A patent/PE20231050A1/es unknown
- 2017-03-02 MA MA45280A patent/MA45280B1/fr unknown
- 2017-03-02 BR BR112018067379A patent/BR112018067379A2/pt active Search and Examination
- 2017-03-02 RS RS20210889A patent/RS62108B1/sr unknown
- 2017-03-02 CN CN202111360093.5A patent/CN114191563A/zh active Pending
- 2017-03-02 MD MDE20190061T patent/MD3423105T2/ro unknown
-
2018
- 2018-02-09 US US15/892,921 patent/US10322192B2/en active Active
- 2018-08-16 CO CONC2018/0008667A patent/CO2018008667A2/es unknown
- 2018-08-28 IL IL261428A patent/IL261428A/en unknown
- 2018-08-28 CL CL2018002456A patent/CL2018002456A1/es unknown
- 2018-08-30 PH PH12018501847A patent/PH12018501847A1/en unknown
- 2018-08-31 MX MX2023003808A patent/MX2023003808A/es unknown
- 2018-08-31 MX MX2023003809A patent/MX2023003809A/es unknown
- 2018-08-31 MX MX2023003806A patent/MX2023003806A/es unknown
-
2019
- 2019-10-01 JP JP2019181469A patent/JP6870051B2/ja active Active
- 2019-12-04 US US16/702,720 patent/US20200297860A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084451A patent/JP2020128413A/ja active Pending
-
2021
- 2021-01-07 CL CL2021000048A patent/CL2021000048A1/es unknown
- 2021-01-07 CL CL2021000049A patent/CL2021000049A1/es unknown
- 2021-02-10 AR ARP210100338A patent/AR121301A2/es unknown
- 2021-02-10 AR ARP210100339A patent/AR121302A2/es unknown
- 2021-04-13 JO JOP/2021/0073A patent/JOP20210073A1/ar unknown
- 2021-04-13 JO JOP/2021/0074A patent/JOP20210074A1/ar unknown
- 2021-07-14 HR HRP20211125TT patent/HRP20211125T1/hr unknown
- 2021-08-02 CY CY20211100686T patent/CY1124628T1/el unknown
- 2021-08-25 JP JP2021137504A patent/JP7254861B2/ja active Active
-
2022
- 2022-12-07 US US18/062,996 patent/US20230398228A1/en active Pending
-
2023
- 2023-03-29 JP JP2023053129A patent/JP2023082096A/ja active Pending
- 2023-12-20 AU AU2023285804A patent/AU2023285804A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000049A1 (es) | Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso (solicitud divisional de 2456-2018) | |
BR112015023333A2 (pt) | pirrolobenzodiazepinas e conjugados das mesmas | |
CR20160271A (es) | Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco | |
CO2019006455A2 (es) | Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas | |
NZ741261A (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
CO2020016137A2 (es) | Conjugados de anticuerpo modulador de empalme–fármaco y métodos de uso | |
AR088694A1 (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos | |
BR112019005247A2 (pt) | terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco | |
CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
CO2021006503A2 (es) | Conjugados de anticuerpo–fármaco de herboxidieno y métodos de uso | |
PE20151603A1 (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos | |
CL2023001266A1 (es) | Composición que comprende una combinación de inhibidor de punto de control inmunitario | |
AR115571A1 (es) | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas | |
AR117589A1 (es) | Conjugados de anticuerpo modulador de empalme-fármaco y métodos de uso | |
AR117686A1 (es) | Modulador de empalme de herboxidieno de conjugados de anticuerpo-fármaco y métodos de uso | |
CO2023008051A2 (es) | Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos | |
AR117405A1 (es) | Uso de conjugados anticuerpo-fármaco que comprenden agentes que alteran la tubulina para tratar tumores sólidos | |
AR098781A1 (es) | Compuestos peptidomiméticos y conjugados anticuerpos-droga de los mismos | |
AR117446A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos |